Influence of Daytime or Nighttime Dosing with Solifenacin for Overactive Bladder with Nocturia: Impact on Nocturia and Sleep Quality.
10.3346/jkms.2017.32.9.1491
- Author:
Taekmin KWON
1
;
Tae Hee OH
;
Seong CHOI
;
Won Yeol CHO
;
Kweonsik MIN
;
Jeong Zoo LEE
;
Kyung Hyun MOON
Author Information
1. Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea. urofirst@hanmail.net
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Urinary Bladder, Overactive;
Solifenacin Succinate;
Nocturia;
Sleep
- MeSH:
Body Mass Index;
Humans;
Korea;
Nocturia*;
Prospective Studies;
Prostate;
Sleep Initiation and Maintenance Disorders;
Solifenacin Succinate*;
Urinary Bladder, Overactive*
- From:Journal of Korean Medical Science
2017;32(9):1491-1495
- CountryRepublic of Korea
- Language:English
-
Abstract:
We compared changes in nocturia and sleep-related parameters between daytime and nighttime solifenacin dosing in patents with overactive bladder (OAB) and nocturia. We comparatively analyzed the data of a 12-week prospective, open-label, multicenter, randomized study. All 127 patients who presented to 5 centers in Korea for the treatment of OAB with nocturia between January 2011 and December 2013 were enrolled in this study. The patients were divided into 2 groups by medication timing: group 1, daytime (n = 62); and group 2, nighttime (n = 65). The International Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score (OABSS), and Athens Insomnia Scale (AIS) were used to assess OAB symptoms and sleep quality. We evaluated the parameter changes before and 12 weeks after daytime or nighttime solifenacin administration. Baseline data, which included sex, age, body mass index (BMI), total AIS, IPSS, and OABSS, did not differ between the 2 groups. Total IPSS, OABSS, and total AIS significantly improved after solifenacin administration regardless of timing (P < 0.001). After solifenacin administration, the number of nocturia episodes decreased in the group 1 and 2 (P < 0.001). There were no significant intergroup differences in changes in AIS, IPSS, OABSS, and number of nocturia episodes 12 weeks after solifenacin administration. Treating OAB with solifenacin may improve nocturia and sleep quality, but advantages did not differ significantly by medication timing.
